Immunotherapy-induced Addison's disease: A rare, persistent and potentially lethal side-effect

Affiliations

¹ Department of Medical Oncology, Institut Curie, Paris, France; Department of Endocrine Oncology, Gustave Roussy, Villejuif, France. Electronic address: segolene.hescot@curie.fr.
² Department of Endocrinology, CHU Bordeaux, Bordeaux, France.
³ Department of Medical Oncology, Gustave Roussy, Villejuif, France.
⁴ Department of Endocrinology, CHU Bicêtre, Le Kremlin-Bicêtre, France.
⁵ Department of Endocrine Oncology, Gustave Roussy, Villejuif, France.

Case Reports

S Hescot et al. Eur J Cancer. 2018 Jul.

. 2018 Jul:97:57-58.

doi: 10.1016/j.ejca.2018.04.001. Epub 2018 May 3.

¹ Department of Medical Oncology, Institut Curie, Paris, France; Department of Endocrine Oncology, Gustave Roussy, Villejuif, France. Electronic address: segolene.hescot@curie.fr.
² Department of Endocrinology, CHU Bordeaux, Bordeaux, France.
³ Department of Medical Oncology, Gustave Roussy, Villejuif, France.
⁴ Department of Endocrinology, CHU Bicêtre, Le Kremlin-Bicêtre, France.
⁵ Department of Endocrine Oncology, Gustave Roussy, Villejuif, France.

No abstract available

Publication types